Breucking E, Mortier W
Institut für Anästhesie, Klinikum Barmen, Wuppertal.
Acta Anaesthesiol Belg. 1990;41(2):127-32.
Neuromuscular diseases raise a lot of anesthesia related problems. The first is the hitherto unknown disease discovered by an unexpected adverse reaction to anesthetics or/and muscle relaxants up to a life-threatening incident. A second problem is the probable, suspected or proven disposition to malignant hyperthermia in patients with other neuromuscular diseases. Furthermore, severe rhabdomyolysis can be induced in myopathic muscle by the application of succinylcholine alone or in combination with inhalational anesthetics resulting in hyperkalemia, myoglobinuria and CK-elevation, sometimes followed by cardiac arrest. Cardiomyopathy is a common feature in many neuromuscular diseases. All cardiodepressant agents must be avoided. Specific problems with muscle relaxants arise in myasthenia gravis and in the myotonias. In the later stages of severe neuromuscular diseases the main problem concerning anesthesia is respiratory failure. The individual risk of every patient has to be evaluated before anesthesia. Recommendations for the anesthetic management are given.
神经肌肉疾病引发了许多与麻醉相关的问题。首先是通过对麻醉剂或/和肌肉松弛剂的意外不良反应直至危及生命的事件发现的迄今未知的疾病。第二个问题是患有其他神经肌肉疾病的患者可能、疑似或已证实存在恶性高热倾向。此外,单独应用琥珀酰胆碱或与吸入性麻醉剂联合应用可在肌病性肌肉中诱发严重横纹肌溶解,导致高钾血症、肌红蛋白尿和肌酸激酶升高,有时随后会发生心脏骤停。心肌病是许多神经肌肉疾病的常见特征。必须避免使用所有心脏抑制药物。重症肌无力和肌强直中会出现与肌肉松弛剂相关的特定问题。在严重神经肌肉疾病的后期,麻醉方面的主要问题是呼吸衰竭。麻醉前必须评估每位患者的个体风险。文中给出了麻醉管理的建议。